Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$27.31 USD
+2.29 (9.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.24 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELVN 27.31 +2.29(9.15%)
Will ELVN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Commit To Purchase Enliven Therapeutics At $17.50, Earn 19.7% Annualized Using Options
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Recommendation for Enliven Therapeutics Based on CML Treatment Market Dynamics and Patient Switching Trends
Analysts Are Bullish on These Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Enliven Therapeutics (ELVN)
Enliven initiated with bullish view at Baird, here's why